Iranian Journal of Pediatrics

Published by: Kowsar

Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya

Hanna Alobaidy 1 , * and Emna Barkaoui 2
Authors Information
1 Department of Pediatrics, Faculty of Medicine, Elkhadra Hospital, Tripoli University, Tripoli, Libya
2 Pasteur Institute, Children’s Hospital, Tunis, Tunisia
Article information
  • Iranian Journal of Pediatrics: October 28, 2015, 25 (5); e3608
  • Published Online: October 6, 2015
  • Article Type: Research Article
  • Received: June 22, 2015
  • Accepted: August 16, 2015
  • DOI: 10.5812/ijp.3608

To Cite: Alobaidy H, Barkaoui E. Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya, Iran J Pediatr. 2015 ; 25(5):e3608. doi: 10.5812/ijp.3608.

Copyright © 2015, Growth & Development Research Center.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med. 1996; 19(5): 311-6[PubMed]
  • 2. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994; 20(5): 1187-91[PubMed]
  • 3. van Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inherit Metab Dis. 1995; 18(2): 111-4[PubMed]
  • 4. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001; 4(3): 212-21[PubMed]
  • 5. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008; 31(1): 81-7[DOI][PubMed]
  • 6. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992; 340(8823): 813-7[PubMed]
  • 7. Schiff M, Broue P, Chabrol B, De Laet C, Habes D, Mention K, et al. Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines. J Inherit Metab Dis. 2012; 35(5): 823-9[DOI][PubMed]
  • 8. El-Karaksy H, Rashed M, El-Sayed R, El-Raziky M, El-Koofy N, El-Hawary M, et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr. 2010; 169(6): 689-93[DOI][PubMed]
  • 9. Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis. 2012; 35(5): 831-6[DOI][PubMed]
  • 10. Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012; 35(2): 263-8[DOI][PubMed]
  • 11. Ben-Omran T. Genetic disorders Among Arab Populations. 2010; : 443-54[DOI]
  • 12. Alobaidy H, Keasta M, Elhoni K. Clinical and biochemical analysis with new advance in management. Jamahiriya Med J. 2004; 3: 37-41
  • 13. Alobaidy H, Yahya N, Said R. Tyrosinemia type I. Clinical and biochemical analysis of cases with poor treatment outcome. Jordan Med J. 2011; 45: 205-11
  • 14. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008; 31(3): 399-402[DOI][PubMed]
  • 15. Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol. 2002; 134(2): 266-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments